The total duration of the study per participant will be up to 38 days including:~A screening period of up to 4 weeks.~A 5-day, open-label treatment period.~Up to 7 days post-treatment follow-up period
The purpose of this parallel group, Phase 1, open-label, 2-arm study is to assess the effect of severe (Part A) and moderate (Part B, conditional) renal impairment (RI) on pharmacokinetics (PK), safety and tolerability of tolebrutinib tablets compared with normal renal function, in male and female participants aged 18 to 79 years.